Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
This study is currently recruiting participants.
Verified June 2012 by C2 Therapeutics, Inc.
Sponsor:
C2 Therapeutics, Inc.
Information provided by (Responsible Party):
C2 Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01293448
First received: December 14, 2010
Last updated: June 28, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate a cryoablation technique used to ablate human esophageal mucosa.
| Condition | Intervention | Phase |
|---|---|---|
|
Barrett's Esophagus Esophageal Cancer |
Device: Cryoballoon Ablation |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium |
Resource links provided by NLM:
Further study details as provided by C2 Therapeutics, Inc.:
Primary Outcome Measures:
- Treatment effect [ Time Frame: Within 30 days of ablation procedure ] [ Designated as safety issue: No ]The primary outcome measure is to evaluate the histological results (depth of injury) of a cryoballoon ablation system.
Secondary Outcome Measures:
- Post-ablation symptoms [ Time Frame: Within 7 days of ablation procedure ] [ Designated as safety issue: Yes ]A secondary outcome measure is to evaluate post-ablation symptoms - number of participants with adverse events as a measure of safety and tolerability.
- Post procedure pain [ Time Frame: Within 7 days of ablation procedure ] [ Designated as safety issue: Yes ]The secondary objective of the study is to determine patient comfort post-procedure. Pain scores are measured on a numerical pain intensity scale.
| Estimated Enrollment: | 20 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Cohort A
Subjects in Cohort A will receive 10 seconds of Cryoballoon Ablation to esophageal tissue for 10 seconds.
|
Device: Cryoballoon Ablation
Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications." (K101825)
Other Names:
|
|
Active Comparator: Cohort B
Subjects in Cohort B will receive 10 seconds of Cryoballoon Ablation to esophageal tissue for 12 seconds.
|
Device: Cryoballoon Ablation
Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications." (K101825)
Other Names:
|
|
Active Comparator: Cohort C
Subjects in Cohort C will receive 10 seconds of Cryoballoon Ablation to esophageal tissue for 14 seconds.
|
Device: Cryoballoon Ablation
Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications." (K101825)
Other Names:
|
Detailed Description:
The purpose of this study is to evaluate the histological results of a cryoablation technique used to ablate human esophageal mucosa. The performance and safety of the cryoablation technique will also be evaluated.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient must have a minimum of 2.0 cm of non-ulcerated, non-inflammatory columnar-lined esophagus or squamous esophageal lined tissue suitable for ablation. A patient may be treated with up to 2 zones of ablation.
- Patient is 18 to 80 years of age at the time of consent (inclusive).
- Patient has provided written Informed Consent Form (IFC) using a form that has been approved by the Institution's reviewing IRB/EC.
- Patient is willing and able to comply with all Clinical Investigation Plan (CIP) requirements.
- Patient's esophagectomy is clinically necessary due to reasons unrelated to this study.
- Patient is deemed operable per standard institutional criteria.
Exclusion Criteria:
- Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to IFC, post treatment instructions or follow-up guidelines.
- Patient refuses or is unable to provide written informed consent. - -
- Patient has or is currently undergoing endoscopic ablation therapy within 4 cm from the proposed treatment area including, but not limited to cryospray therapy, laser treatment, photodynamic therapy, multi-polar electro coagulation, endoscopic mucosal resection, radiofrequency ablation or argon plasma coagulation.
- Patient has esophageal narrowing limiting access to the intended site of ablation.
- Patient is undergoing or has recently undergone chemotherapy (within 15 days or WBC below normal by institutional criteria or standards).
- Patient is undergoing or has recently undergone radiation therapy which involved the esophagus (within 15 days or WBC below normal by institutional criteria or standards).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01293448
Locations
| United States, California | |
| University of Southern California | Completed |
| Los Angeles, California, United States, 90033 | |
| United States, New York | |
| University of Rochester | Completed |
| Rochester, New York, United States, 14642 | |
| United States, Pennsylvania | |
| University of Pittsburgh | Completed |
| Pittsburgh, Pennsylvania, United States, 15232 | |
| Netherlands | |
| AMC | Recruiting |
| Amsterdam, AZ, Netherlands, 1105 | |
| Contact: Dirk Scholvinck, MD d.w.scholvinck@amc.uva.nl | |
| Principal Investigator: Jacques Bergman, MD | |
Sponsors and Collaborators
C2 Therapeutics, Inc.
Investigators
| Principal Investigator: | Jacques Bergman, MD | AIDS Malignancy Clinical Trials Consortium |
| Principal Investigator: | Steve DeMeester, MD | University of Southern California |
| Principal Investigator: | Blair Jobe, MD | University of Pittsburgh |
| Principal Investigator: | Jeffery Peters, MD | University of Rochester |
More Information
No publications provided
| Responsible Party: | C2 Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT01293448 History of Changes |
| Other Study ID Numbers: | CP-0001.A |
| Study First Received: | December 14, 2010 |
| Last Updated: | June 28, 2012 |
| Health Authority: | United States: Institutional Review Board Netherlands: Independent Ethics Committee |
Keywords provided by C2 Therapeutics, Inc.:
|
Esophagectomy Barrett's Esophagus |
Additional relevant MeSH terms:
|
Barrett Esophagus Esophageal Diseases Esophageal Neoplasms Digestive System Abnormalities Digestive System Diseases Gastrointestinal Diseases |
Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms |
ClinicalTrials.gov processed this record on May 23, 2013